Planned international multicenter, open-label, randomized modular phase III successor trial to HR2 to improve patient outcomes and decrease toxicities for patients with front-line high-risk neuroblastoma building on results from HR2 and pilot trials.

BEACON2 is a platform multi-arm multi-stage (MAMS) randomised phase I/phase II, open-label, international trial for participants with relapsed neuroblastoma.